Literature DB >> 10071586

Evaluation of the allograft-prosthesis composite technique for proximal femoral reconstruction after resection of a primary bone tumour.

B M McGoveran1, A M Davis, A E Gross, R S Bell.   

Abstract

OBJECTIVE: To evaluate clinical and functional outcomes resulting from the allograft-composite technique used for proximal femoral osteoarticular reconstruction in patients who had limb salvage surgery for primary bone tumours.
DESIGN: A retrospective review of a prospectively gathered database to provide a descriptive study.
SETTING: A tertiary care musculoskeletal oncology unit in a university hospital. PATIENTS AND
INTERVENTIONS: Patients treated between 1987 and 1993 were eligible for inclusion in this study if they met the following criteria: they were treated surgically for a primary malignant bone tumour; and a proximal femoral allograft-implant composite technique was used for the reconstruction. MAIN OUTCOME MEASURES: Major postoperative complications with emphasis on mechanical complications in the reconstructive composite implant. Functional outcome in a subset of patients using the 1987 and 1994 versions of the Musculoskeletal Tumor Society instrument, the Short-Form-36 and the Toronto Extremity Salvage Score.
RESULTS: There were 5 mechanical and 2 infectious complications requiring surgical intervention. Functional scores were generally low.
CONCLUSIONS: Our results suggest that the perceived benefits of the composite technique may accrue only to a few patients, partly owing to the risk of mechanical complications. Although these can be reduced by avoiding the use of cement in the host femur, the generally poor functional outcomes suggest that this technique needs to be studied further in this group of patients and compared with other reconstructive techniques, particularly the prosthetic implant.

Entities:  

Mesh:

Year:  1999        PMID: 10071586      PMCID: PMC3788880     

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  7 in total

Review 1.  Megaprosthesis versus Allograft Prosthesis Composite for massive skeletal defects.

Authors:  Deepak Gautam; Rajesh Malhotra
Journal:  J Clin Orthop Trauma       Date:  2017-09-25

2.  Implant and limb survival after resection of primary bone tumors of the lower extremities and reconstruction with mega-prostheses fifty patients followed for a mean of forteen years.

Authors:  Christina Enciso Holm; Christian Bardram; Anja Falk Riecke; Peter Horstmann; Michael Mørk Petersen
Journal:  Int Orthop       Date:  2018-03-12       Impact factor: 3.075

3.  Does Local Zoledronate Applied to Pasteurized Bone Autografts Improve the Likelihood of Union of Graft-Host Junctions after Limb-sparing Surgery?

Authors:  Piya Kiatisevi; Bhasanan Sukanthanak; Pongsiri Piakong; Piyabuth Kittithamvongs
Journal:  Clin Orthop Relat Res       Date:  2022-01-01       Impact factor: 4.755

4.  Results of 32 allograft-prosthesis composite reconstructions of the proximal femur.

Authors:  David J Biau; Frédérique Larousserie; Fabrice Thévenin; Sophie Piperno-Neumann; Philippe Anract
Journal:  Clin Orthop Relat Res       Date:  2009-10-23       Impact factor: 4.176

5.  Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours--a comparative analysis using the MSTS score, the TESS and the RNL index.

Authors:  P U Tunn; D Pomraenke; U Goerling; P Hohenberger
Journal:  Int Orthop       Date:  2007-08-15       Impact factor: 3.075

6.  Long-term results of uncemented allograft prosthesis composite reconstruction for the tumor in proximal femur: a minimum follow-up of sixty-five months.

Authors:  Cai Liu; Li Min; Yong Zhou; Yi Luo; Fan Tang; Minxun Lu; Hong Duan; Wenli Zhang; Xinzhu Yu; Chongqi Tu
Journal:  BMC Musculoskelet Disord       Date:  2021-02-01       Impact factor: 2.362

7.  Uncemented allograft-prosthetic composite reconstruction of the proximal femur.

Authors:  Li Min; Jing Peng; Hong Duan; Wenli Zhang; Yong Zhou; Chongqi Tu
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.